| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Liver Transplantation | 52 | 2025 | 1102 | 7.910 |
Why?
|
| Liver Cirrhosis | 34 | 2024 | 898 | 6.430 |
Why?
|
| End Stage Liver Disease | 18 | 2025 | 191 | 3.890 |
Why?
|
| Tissue Donors | 14 | 2019 | 503 | 3.430 |
Why?
|
| Carcinoma, Hepatocellular | 30 | 2023 | 984 | 3.170 |
Why?
|
| Liver Neoplasms | 31 | 2023 | 1381 | 2.950 |
Why?
|
| Waiting Lists | 20 | 2024 | 236 | 2.340 |
Why?
|
| Liver Diseases | 8 | 2022 | 385 | 2.220 |
Why?
|
| Tissue and Organ Procurement | 12 | 2018 | 246 | 2.190 |
Why?
|
| Frailty | 10 | 2025 | 135 | 1.900 |
Why?
|
| Hepatic Encephalopathy | 7 | 2024 | 84 | 1.730 |
Why?
|
| Patient Readmission | 5 | 2024 | 424 | 1.700 |
Why?
|
| Patient Selection | 11 | 2020 | 730 | 1.450 |
Why?
|
| Hepatitis C | 5 | 2019 | 387 | 1.270 |
Why?
|
| Graft Rejection | 5 | 2023 | 558 | 1.220 |
Why?
|
| Quality of Life | 8 | 2022 | 2149 | 1.130 |
Why?
|
| Hepatitis C, Chronic | 6 | 2019 | 370 | 1.110 |
Why?
|
| Humans | 128 | 2025 | 131930 | 1.100 |
Why?
|
| Donor Selection | 3 | 2017 | 58 | 1.080 |
Why?
|
| Decision Support Techniques | 6 | 2018 | 309 | 1.060 |
Why?
|
| Early Detection of Cancer | 4 | 2023 | 413 | 1.020 |
Why?
|
| Antiviral Agents | 6 | 2019 | 822 | 1.010 |
Why?
|
| Quality Indicators, Health Care | 5 | 2024 | 227 | 1.010 |
Why?
|
| Disease Management | 3 | 2018 | 564 | 0.990 |
Why?
|
| United States | 34 | 2024 | 11619 | 0.960 |
Why?
|
| Gastroenterology | 3 | 2022 | 211 | 0.950 |
Why?
|
| Alcoholism | 4 | 2021 | 250 | 0.940 |
Why?
|
| Quality of Health Care | 5 | 2017 | 418 | 0.930 |
Why?
|
| Organ Transplantation | 2 | 2017 | 180 | 0.890 |
Why?
|
| Patient Acceptance of Health Care | 6 | 2023 | 479 | 0.890 |
Why?
|
| Insurance, Health | 3 | 2019 | 144 | 0.860 |
Why?
|
| Telemedicine | 2 | 2022 | 506 | 0.820 |
Why?
|
| alpha-Fetoproteins | 5 | 2021 | 134 | 0.810 |
Why?
|
| Risk Factors | 28 | 2025 | 10893 | 0.800 |
Why?
|
| Cholangiopancreatography, Endoscopic Retrograde | 3 | 2019 | 81 | 0.790 |
Why?
|
| Middle Aged | 52 | 2025 | 28893 | 0.770 |
Why?
|
| Health Knowledge, Attitudes, Practice | 6 | 2017 | 897 | 0.760 |
Why?
|
| Choice Behavior | 2 | 2015 | 130 | 0.750 |
Why?
|
| Patient Participation | 3 | 2015 | 240 | 0.750 |
Why?
|
| Palliative Care | 4 | 2022 | 457 | 0.750 |
Why?
|
| Liver | 6 | 2021 | 1799 | 0.730 |
Why?
|
| Contracts | 2 | 2011 | 11 | 0.720 |
Why?
|
| Reimbursement Mechanisms | 2 | 2019 | 35 | 0.720 |
Why?
|
| Patient Education as Topic | 4 | 2014 | 461 | 0.700 |
Why?
|
| Aged | 37 | 2025 | 21394 | 0.700 |
Why?
|
| Lactulose | 1 | 2021 | 29 | 0.690 |
Why?
|
| Adult | 43 | 2025 | 31506 | 0.670 |
Why?
|
| Female | 64 | 2025 | 70607 | 0.660 |
Why?
|
| Quality Improvement | 3 | 2022 | 695 | 0.660 |
Why?
|
| Patient Reported Outcome Measures | 3 | 2022 | 211 | 0.650 |
Why?
|
| Viremia | 2 | 2018 | 133 | 0.650 |
Why?
|
| Male | 62 | 2025 | 64846 | 0.650 |
Why?
|
| Social Discrimination | 1 | 2019 | 5 | 0.640 |
Why?
|
| Cholelithiasis | 1 | 2019 | 18 | 0.640 |
Why?
|
| Social Support | 4 | 2017 | 386 | 0.630 |
Why?
|
| Transplant Recipients | 3 | 2023 | 225 | 0.610 |
Why?
|
| Physician-Patient Relations | 3 | 2011 | 447 | 0.610 |
Why?
|
| Chronic Disease | 5 | 2018 | 1226 | 0.600 |
Why?
|
| Lung Transplantation | 1 | 2023 | 336 | 0.600 |
Why?
|
| Liver Cirrhosis, Alcoholic | 5 | 2021 | 40 | 0.580 |
Why?
|
| Positron-Emission Tomography | 1 | 2020 | 311 | 0.580 |
Why?
|
| Hepatitis B | 2 | 2017 | 171 | 0.580 |
Why?
|
| Death | 1 | 2019 | 78 | 0.570 |
Why?
|
| Health Equity | 1 | 2019 | 73 | 0.560 |
Why?
|
| Ascites | 5 | 2019 | 103 | 0.560 |
Why?
|
| Radiopharmaceuticals | 1 | 2018 | 170 | 0.550 |
Why?
|
| Neoplasm Metastasis | 1 | 2020 | 722 | 0.550 |
Why?
|
| United States Public Health Service | 1 | 2017 | 5 | 0.550 |
Why?
|
| Liver Diseases, Alcoholic | 1 | 2018 | 59 | 0.530 |
Why?
|
| Models, Theoretical | 2 | 2019 | 390 | 0.520 |
Why?
|
| Neoplasm Recurrence, Local | 2 | 2020 | 1303 | 0.510 |
Why?
|
| Cost of Illness | 3 | 2018 | 275 | 0.510 |
Why?
|
| Embolization, Therapeutic | 1 | 2018 | 223 | 0.490 |
Why?
|
| Fetus | 1 | 2019 | 595 | 0.490 |
Why?
|
| Aspartate Aminotransferases | 1 | 2015 | 84 | 0.470 |
Why?
|
| Delivery of Health Care | 2 | 2022 | 680 | 0.470 |
Why?
|
| Hospitalization | 5 | 2021 | 1892 | 0.460 |
Why?
|
| Practice Patterns, Physicians' | 4 | 2017 | 764 | 0.460 |
Why?
|
| Subcutaneous Fat | 1 | 2015 | 35 | 0.460 |
Why?
|
| Intra-Abdominal Fat | 1 | 2015 | 60 | 0.450 |
Why?
|
| Pregnancy Complications | 1 | 2019 | 550 | 0.440 |
Why?
|
| Time Factors | 15 | 2019 | 6435 | 0.440 |
Why?
|
| Treatment Outcome | 18 | 2023 | 12996 | 0.430 |
Why?
|
| Drug Approval | 1 | 2014 | 45 | 0.430 |
Why?
|
| Health Care Costs | 4 | 2021 | 407 | 0.430 |
Why?
|
| Self Care | 2 | 2013 | 227 | 0.420 |
Why?
|
| Health Care Rationing | 2 | 2011 | 63 | 0.420 |
Why?
|
| Aftercare | 3 | 2024 | 155 | 0.420 |
Why?
|
| Heart Diseases | 1 | 2018 | 511 | 0.420 |
Why?
|
| Prejudice | 1 | 2013 | 38 | 0.410 |
Why?
|
| Social Stigma | 1 | 2013 | 85 | 0.400 |
Why?
|
| Lung Neoplasms | 1 | 2023 | 1540 | 0.400 |
Why?
|
| Health Services Administration | 1 | 2012 | 9 | 0.390 |
Why?
|
| Survival Analysis | 5 | 2014 | 1569 | 0.390 |
Why?
|
| Patient Admission | 1 | 2013 | 185 | 0.380 |
Why?
|
| Graft Survival | 6 | 2023 | 471 | 0.380 |
Why?
|
| Health Status Disparities | 1 | 2015 | 251 | 0.380 |
Why?
|
| Young Adult | 14 | 2019 | 9929 | 0.380 |
Why?
|
| Decision Making | 3 | 2013 | 694 | 0.370 |
Why?
|
| Tacrolimus | 1 | 2012 | 104 | 0.370 |
Why?
|
| Retirement | 1 | 2012 | 18 | 0.370 |
Why?
|
| Postoperative Complications | 6 | 2019 | 3129 | 0.370 |
Why?
|
| Poverty | 1 | 2015 | 434 | 0.370 |
Why?
|
| Interdisciplinary Communication | 1 | 2012 | 133 | 0.360 |
Why?
|
| Hospitals | 1 | 2014 | 437 | 0.360 |
Why?
|
| Health Behavior | 2 | 2011 | 398 | 0.350 |
Why?
|
| Michigan | 5 | 2015 | 50 | 0.350 |
Why?
|
| Advisory Committees | 1 | 2011 | 151 | 0.340 |
Why?
|
| Radiology | 2 | 2023 | 126 | 0.340 |
Why?
|
| Patients | 1 | 2011 | 127 | 0.340 |
Why?
|
| Risk Assessment | 9 | 2025 | 3710 | 0.340 |
Why?
|
| Biomarkers | 2 | 2012 | 3373 | 0.330 |
Why?
|
| Chemoembolization, Therapeutic | 2 | 2023 | 26 | 0.330 |
Why?
|
| Incidental Findings | 1 | 2011 | 130 | 0.330 |
Why?
|
| Hospitals, Veterans | 1 | 2012 | 348 | 0.320 |
Why?
|
| Risk | 4 | 2021 | 761 | 0.320 |
Why?
|
| Medicare | 2 | 2022 | 447 | 0.320 |
Why?
|
| Comorbidity | 4 | 2025 | 1604 | 0.320 |
Why?
|
| Surveys and Questionnaires | 11 | 2021 | 3977 | 0.320 |
Why?
|
| Attitude to Death | 1 | 2010 | 39 | 0.310 |
Why?
|
| Living Donors | 2 | 2008 | 116 | 0.310 |
Why?
|
| Quality Assurance, Health Care | 1 | 2011 | 216 | 0.310 |
Why?
|
| Aged, 80 and over | 10 | 2019 | 7113 | 0.310 |
Why?
|
| Retrospective Studies | 20 | 2023 | 17345 | 0.310 |
Why?
|
| Severity of Illness Index | 10 | 2021 | 3082 | 0.300 |
Why?
|
| Alcohol Drinking | 3 | 2019 | 359 | 0.300 |
Why?
|
| Markov Chains | 7 | 2013 | 98 | 0.300 |
Why?
|
| Diabetes Mellitus | 2 | 2015 | 922 | 0.290 |
Why?
|
| Directed Tissue Donation | 1 | 2008 | 3 | 0.290 |
Why?
|
| Resource Allocation | 1 | 2008 | 53 | 0.290 |
Why?
|
| Policy Making | 1 | 2008 | 61 | 0.290 |
Why?
|
| Altruism | 1 | 2008 | 25 | 0.290 |
Why?
|
| Proton Therapy | 2 | 2023 | 159 | 0.290 |
Why?
|
| Immunosuppressive Agents | 1 | 2012 | 672 | 0.290 |
Why?
|
| Gift Giving | 1 | 2008 | 18 | 0.290 |
Why?
|
| Patient-Centered Care | 2 | 2022 | 232 | 0.280 |
Why?
|
| Liver Failure | 1 | 2008 | 91 | 0.280 |
Why?
|
| HIV Infections | 2 | 2017 | 2048 | 0.270 |
Why?
|
| Death, Sudden, Cardiac | 1 | 2010 | 269 | 0.270 |
Why?
|
| Public Health | 1 | 2009 | 280 | 0.270 |
Why?
|
| Neoplasm Transplantation | 1 | 2008 | 383 | 0.270 |
Why?
|
| Health Services Needs and Demand | 3 | 2017 | 174 | 0.250 |
Why?
|
| Health Personnel | 1 | 2011 | 545 | 0.250 |
Why?
|
| Caregivers | 1 | 2012 | 595 | 0.250 |
Why?
|
| Proportional Hazards Models | 6 | 2025 | 1450 | 0.250 |
Why?
|
| Protein Precursors | 1 | 2007 | 156 | 0.250 |
Why?
|
| Motivation | 1 | 2008 | 329 | 0.240 |
Why?
|
| Cardiovascular Diseases | 1 | 2018 | 2059 | 0.240 |
Why?
|
| Inpatients | 2 | 2024 | 553 | 0.240 |
Why?
|
| Cost-Benefit Analysis | 3 | 2017 | 551 | 0.230 |
Why?
|
| Patient Discharge | 2 | 2024 | 511 | 0.220 |
Why?
|
| Liver Failure, Acute | 2 | 2021 | 94 | 0.220 |
Why?
|
| Hepacivirus | 3 | 2018 | 272 | 0.220 |
Why?
|
| Healthcare Disparities | 1 | 2009 | 482 | 0.220 |
Why?
|
| Outpatients | 2 | 2024 | 275 | 0.210 |
Why?
|
| Follow-Up Studies | 5 | 2018 | 5394 | 0.210 |
Why?
|
| Transplants | 1 | 2023 | 36 | 0.200 |
Why?
|
| Acute Disease | 2 | 2021 | 1161 | 0.200 |
Why?
|
| Linear Models | 3 | 2016 | 709 | 0.200 |
Why?
|
| Health Surveys | 2 | 2013 | 259 | 0.190 |
Why?
|
| Prospective Studies | 6 | 2025 | 6526 | 0.190 |
Why?
|
| Databases, Factual | 3 | 2018 | 1228 | 0.180 |
Why?
|
| Delphi Technique | 2 | 2024 | 240 | 0.180 |
Why?
|
| Gastroenterologists | 1 | 2021 | 12 | 0.180 |
Why?
|
| Alcohol Abstinence | 2 | 2018 | 17 | 0.180 |
Why?
|
| Practice Guidelines as Topic | 1 | 2008 | 1303 | 0.180 |
Why?
|
| Hospice and Palliative Care Nursing | 1 | 2021 | 18 | 0.180 |
Why?
|
| Adolescent | 8 | 2019 | 20524 | 0.180 |
Why?
|
| Clinical Decision-Making | 3 | 2018 | 303 | 0.170 |
Why?
|
| Cross-Sectional Studies | 4 | 2017 | 3735 | 0.170 |
Why?
|
| Survival Rate | 4 | 2016 | 2183 | 0.170 |
Why?
|
| Sex Factors | 4 | 2021 | 1348 | 0.170 |
Why?
|
| Incidence | 5 | 2019 | 3362 | 0.170 |
Why?
|
| Gastrointestinal Agents | 1 | 2021 | 64 | 0.170 |
Why?
|
| Critical Care | 1 | 2006 | 686 | 0.170 |
Why?
|
| Recurrence | 3 | 2018 | 1451 | 0.160 |
Why?
|
| Civil Rights | 1 | 2019 | 10 | 0.160 |
Why?
|
| Activities of Daily Living | 3 | 2017 | 428 | 0.160 |
Why?
|
| Anti-Inflammatory Agents | 1 | 2022 | 305 | 0.160 |
Why?
|
| Gastric Bypass | 1 | 2021 | 80 | 0.160 |
Why?
|
| Policy | 1 | 2019 | 37 | 0.160 |
Why?
|
| Prisoners | 1 | 2019 | 38 | 0.150 |
Why?
|
| Religion | 1 | 2019 | 51 | 0.150 |
Why?
|
| Internet | 2 | 2014 | 405 | 0.150 |
Why?
|
| Prevalence | 3 | 2018 | 2656 | 0.150 |
Why?
|
| Heart Failure, Systolic | 1 | 2019 | 35 | 0.150 |
Why?
|
| Radiation Exposure | 1 | 2019 | 50 | 0.150 |
Why?
|
| Bariatric Surgery | 1 | 2021 | 139 | 0.150 |
Why?
|
| Prognosis | 6 | 2018 | 5004 | 0.150 |
Why?
|
| Seroconversion | 1 | 2018 | 15 | 0.150 |
Why?
|
| Liver Function Tests | 2 | 2016 | 103 | 0.150 |
Why?
|
| Advance Care Planning | 1 | 2019 | 41 | 0.150 |
Why?
|
| Age Factors | 4 | 2017 | 2920 | 0.150 |
Why?
|
| Rupture, Spontaneous | 1 | 2018 | 47 | 0.150 |
Why?
|
| Hepatitis C Antibodies | 1 | 2018 | 24 | 0.150 |
Why?
|
| Health Services Accessibility | 2 | 2016 | 656 | 0.140 |
Why?
|
| Hepatitis, Alcoholic | 1 | 2018 | 29 | 0.140 |
Why?
|
| Biomarkers, Tumor | 1 | 2007 | 1683 | 0.140 |
Why?
|
| Obesity, Morbid | 1 | 2021 | 211 | 0.140 |
Why?
|
| Patient Care Planning | 1 | 2019 | 130 | 0.140 |
Why?
|
| Sepsis | 1 | 2022 | 515 | 0.140 |
Why?
|
| Comprehension | 2 | 2023 | 81 | 0.140 |
Why?
|
| Fibrosis | 2 | 2016 | 423 | 0.140 |
Why?
|
| Fatal Outcome | 1 | 2018 | 376 | 0.140 |
Why?
|
| Lymphoma, Mantle-Cell | 1 | 2017 | 31 | 0.130 |
Why?
|
| Induction Chemotherapy | 1 | 2017 | 56 | 0.130 |
Why?
|
| Acute-On-Chronic Liver Failure | 1 | 2018 | 78 | 0.130 |
Why?
|
| Renal Insufficiency | 2 | 2011 | 254 | 0.130 |
Why?
|
| Fee-for-Service Plans | 1 | 2017 | 18 | 0.130 |
Why?
|
| Computed Tomography Angiography | 1 | 2018 | 215 | 0.130 |
Why?
|
| Rituximab | 1 | 2017 | 166 | 0.130 |
Why?
|
| Feedback | 2 | 2021 | 166 | 0.130 |
Why?
|
| Depression | 2 | 2017 | 1350 | 0.130 |
Why?
|
| Antineoplastic Agents, Immunological | 1 | 2017 | 127 | 0.120 |
Why?
|
| RNA, Viral | 1 | 2018 | 565 | 0.120 |
Why?
|
| Non-alcoholic Fatty Liver Disease | 1 | 2021 | 419 | 0.120 |
Why?
|
| Cohort Studies | 5 | 2021 | 5143 | 0.120 |
Why?
|
| Multivariate Analysis | 3 | 2014 | 1439 | 0.120 |
Why?
|
| Patient Satisfaction | 1 | 2019 | 478 | 0.120 |
Why?
|
| Point-of-Care Systems | 1 | 2018 | 193 | 0.120 |
Why?
|
| Laparoscopy | 1 | 2021 | 521 | 0.120 |
Why?
|
| Italy | 3 | 2014 | 130 | 0.120 |
Why?
|
| Life Style | 2 | 2021 | 452 | 0.120 |
Why?
|
| Ethics, Medical | 1 | 2018 | 401 | 0.110 |
Why?
|
| Interviews as Topic | 2 | 2018 | 424 | 0.110 |
Why?
|
| Drug Therapy, Combination | 2 | 2017 | 1176 | 0.110 |
Why?
|
| Preoperative Care | 3 | 2024 | 368 | 0.110 |
Why?
|
| Drug Utilization | 2 | 2019 | 165 | 0.110 |
Why?
|
| Cardiomyopathies | 1 | 2019 | 509 | 0.110 |
Why?
|
| Health Status | 2 | 2018 | 406 | 0.110 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2019 | 1246 | 0.110 |
Why?
|
| Health Care Reform | 1 | 2014 | 52 | 0.110 |
Why?
|
| Health Care Surveys | 2 | 2012 | 292 | 0.110 |
Why?
|
| Neuropsychological Tests | 1 | 2018 | 989 | 0.110 |
Why?
|
| Coronary Artery Disease | 1 | 2021 | 891 | 0.110 |
Why?
|
| Nutrition Surveys | 1 | 2015 | 312 | 0.100 |
Why?
|
| Fluorouracil | 1 | 2013 | 139 | 0.100 |
Why?
|
| Deoxycytidine | 1 | 2013 | 83 | 0.100 |
Why?
|
| Age of Onset | 1 | 2015 | 626 | 0.100 |
Why?
|
| Longitudinal Studies | 2 | 2019 | 1493 | 0.100 |
Why?
|
| User-Computer Interface | 1 | 2014 | 168 | 0.100 |
Why?
|
| Viral Load | 2 | 2018 | 408 | 0.100 |
Why?
|
| Pamphlets | 1 | 2013 | 24 | 0.100 |
Why?
|
| Disease Progression | 3 | 2011 | 2222 | 0.100 |
Why?
|
| Bile Duct Diseases | 1 | 2012 | 17 | 0.100 |
Why?
|
| Kidney Transplantation | 1 | 2018 | 567 | 0.100 |
Why?
|
| Societies, Medical | 1 | 2017 | 778 | 0.100 |
Why?
|
| Probability | 1 | 2013 | 322 | 0.100 |
Why?
|
| Brain Death | 1 | 2013 | 70 | 0.100 |
Why?
|
| Ambulatory Care | 1 | 2016 | 412 | 0.100 |
Why?
|
| Cholangiocarcinoma | 1 | 2013 | 122 | 0.090 |
Why?
|
| Radiosurgery | 1 | 2013 | 147 | 0.090 |
Why?
|
| Predictive Value of Tests | 5 | 2018 | 2303 | 0.090 |
Why?
|
| Fund Raising | 1 | 2011 | 5 | 0.090 |
Why?
|
| Computer Graphics | 1 | 2011 | 38 | 0.090 |
Why?
|
| Direct Service Costs | 1 | 2011 | 11 | 0.090 |
Why?
|
| Paternalism | 1 | 2011 | 30 | 0.090 |
Why?
|
| Sigmoidoscopy | 1 | 2011 | 10 | 0.090 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2023 | 3852 | 0.090 |
Why?
|
| Registries | 3 | 2018 | 1588 | 0.090 |
Why?
|
| Hospitals, Private | 1 | 2011 | 23 | 0.090 |
Why?
|
| Tomography, X-Ray Computed | 2 | 2022 | 2163 | 0.090 |
Why?
|
| Hospitals, University | 1 | 2011 | 104 | 0.090 |
Why?
|
| Diet | 2 | 2021 | 1124 | 0.090 |
Why?
|
| Cholangiopancreatography, Magnetic Resonance | 1 | 2011 | 11 | 0.090 |
Why?
|
| Risk-Taking | 1 | 2011 | 101 | 0.090 |
Why?
|
| Disability Evaluation | 1 | 2012 | 194 | 0.090 |
Why?
|
| Benchmarking | 2 | 2022 | 137 | 0.090 |
Why?
|
| Algorithms | 1 | 2018 | 1720 | 0.090 |
Why?
|
| Regression Analysis | 2 | 2009 | 795 | 0.080 |
Why?
|
| Hemorrhage | 2 | 2011 | 517 | 0.080 |
Why?
|
| Chi-Square Distribution | 1 | 2011 | 586 | 0.080 |
Why?
|
| Anxiety | 1 | 2017 | 1001 | 0.080 |
Why?
|
| Benzenesulfonates | 1 | 2010 | 12 | 0.080 |
Why?
|
| Patient Preference | 1 | 2011 | 136 | 0.080 |
Why?
|
| Odds Ratio | 2 | 2011 | 1255 | 0.080 |
Why?
|
| Population Surveillance | 1 | 2012 | 415 | 0.080 |
Why?
|
| Pilot Projects | 1 | 2014 | 1450 | 0.080 |
Why?
|
| Attitude | 1 | 2010 | 120 | 0.080 |
Why?
|
| Kaplan-Meier Estimate | 2 | 2014 | 1124 | 0.080 |
Why?
|
| Clinical Competence | 1 | 2017 | 1070 | 0.080 |
Why?
|
| Public Opinion | 1 | 2010 | 62 | 0.080 |
Why?
|
| Medicaid | 1 | 2012 | 246 | 0.080 |
Why?
|
| Geography | 1 | 2009 | 122 | 0.080 |
Why?
|
| Health Policy | 1 | 2011 | 228 | 0.080 |
Why?
|
| Random Allocation | 1 | 2010 | 431 | 0.080 |
Why?
|
| Cholestasis | 1 | 2011 | 157 | 0.070 |
Why?
|
| Medical Informatics | 1 | 2010 | 110 | 0.070 |
Why?
|
| Sensitivity and Specificity | 3 | 2011 | 2141 | 0.070 |
Why?
|
| Pyridines | 1 | 2010 | 249 | 0.070 |
Why?
|
| Data Collection | 1 | 2010 | 390 | 0.070 |
Why?
|
| Beneficence | 1 | 2008 | 84 | 0.070 |
Why?
|
| Exercise Test | 2 | 2021 | 256 | 0.070 |
Why?
|
| Moral Obligations | 1 | 2008 | 76 | 0.070 |
Why?
|
| Qualitative Research | 1 | 2011 | 661 | 0.070 |
Why?
|
| Emigrants and Immigrants | 1 | 2010 | 157 | 0.070 |
Why?
|
| Neoplasm Staging | 2 | 2014 | 1363 | 0.070 |
Why?
|
| Antineoplastic Agents | 3 | 2016 | 1828 | 0.070 |
Why?
|
| Niacinamide | 2 | 2022 | 31 | 0.070 |
Why?
|
| Connective Tissue Diseases | 1 | 2007 | 32 | 0.070 |
Why?
|
| Communication | 1 | 2011 | 540 | 0.070 |
Why?
|
| Early Diagnosis | 1 | 2008 | 198 | 0.070 |
Why?
|
| Prothrombin | 1 | 2007 | 26 | 0.070 |
Why?
|
| Lectins | 1 | 2007 | 49 | 0.070 |
Why?
|
| Pregnancy | 1 | 2019 | 7545 | 0.060 |
Why?
|
| Physicians | 1 | 2013 | 637 | 0.060 |
Why?
|
| Mass Screening | 1 | 2012 | 830 | 0.060 |
Why?
|
| Propensity Score | 2 | 2019 | 255 | 0.060 |
Why?
|
| Case Management | 1 | 2006 | 19 | 0.060 |
Why?
|
| Hemorrhagic Disorders | 1 | 2006 | 22 | 0.060 |
Why?
|
| Area Under Curve | 1 | 2007 | 319 | 0.060 |
Why?
|
| Peritonitis | 1 | 2006 | 76 | 0.060 |
Why?
|
| Hepatorenal Syndrome | 1 | 2006 | 28 | 0.060 |
Why?
|
| Length of Stay | 1 | 2011 | 1379 | 0.060 |
Why?
|
| Case-Control Studies | 1 | 2012 | 3415 | 0.060 |
Why?
|
| Esophageal and Gastric Varices | 1 | 2006 | 76 | 0.060 |
Why?
|
| Hypertension, Portal | 1 | 2006 | 78 | 0.060 |
Why?
|
| Colorectal Neoplasms | 1 | 2011 | 629 | 0.060 |
Why?
|
| Infant | 2 | 2017 | 13032 | 0.060 |
Why?
|
| Stroke | 1 | 2013 | 1081 | 0.060 |
Why?
|
| ROC Curve | 1 | 2007 | 598 | 0.060 |
Why?
|
| Family | 1 | 2008 | 594 | 0.060 |
Why?
|
| Child, Preschool | 2 | 2017 | 14715 | 0.060 |
Why?
|
| Infant, Newborn | 1 | 2017 | 8535 | 0.050 |
Why?
|
| Gastrointestinal Hemorrhage | 1 | 2006 | 237 | 0.050 |
Why?
|
| Virus Diseases | 1 | 2007 | 289 | 0.050 |
Why?
|
| Coronary Disease | 1 | 2007 | 683 | 0.050 |
Why?
|
| Quality-Adjusted Life Years | 2 | 2017 | 128 | 0.050 |
Why?
|
| Protons | 1 | 2023 | 98 | 0.050 |
Why?
|
| Reading | 1 | 2023 | 78 | 0.050 |
Why?
|
| Kidney | 1 | 2009 | 1326 | 0.050 |
Why?
|
| Pantothenic Acid | 1 | 2022 | 6 | 0.050 |
Why?
|
| Pyridoxine | 1 | 2022 | 15 | 0.050 |
Why?
|
| Thiamine | 1 | 2022 | 9 | 0.050 |
Why?
|
| Riboflavin | 1 | 2022 | 32 | 0.050 |
Why?
|
| Ascorbic Acid | 1 | 2022 | 76 | 0.050 |
Why?
|
| Magnesium Sulfate | 1 | 2022 | 51 | 0.050 |
Why?
|
| Loneliness | 1 | 2022 | 34 | 0.050 |
Why?
|
| Computers | 1 | 2022 | 69 | 0.050 |
Why?
|
| Monte Carlo Method | 2 | 2013 | 102 | 0.040 |
Why?
|
| Smoking | 1 | 2007 | 940 | 0.040 |
Why?
|
| Drug Combinations | 1 | 2022 | 280 | 0.040 |
Why?
|
| Abdomen | 1 | 2022 | 135 | 0.040 |
Why?
|
| Alanine Transaminase | 1 | 2021 | 162 | 0.040 |
Why?
|
| Logistic Models | 2 | 2019 | 1835 | 0.040 |
Why?
|
| Hand Strength | 1 | 2021 | 60 | 0.040 |
Why?
|
| Dexamethasone | 1 | 2022 | 274 | 0.040 |
Why?
|
| Pulmonary Disease, Chronic Obstructive | 1 | 2007 | 628 | 0.040 |
Why?
|
| Child | 2 | 2017 | 25756 | 0.040 |
Why?
|
| Postural Balance | 1 | 2021 | 131 | 0.040 |
Why?
|
| Tumor Burden | 1 | 2020 | 248 | 0.040 |
Why?
|
| Protective Factors | 1 | 2019 | 90 | 0.040 |
Why?
|
| Preoperative Period | 1 | 2019 | 91 | 0.040 |
Why?
|
| Karnofsky Performance Status | 1 | 2018 | 13 | 0.040 |
Why?
|
| Sustained Virologic Response | 1 | 2019 | 46 | 0.040 |
Why?
|
| Critical Illness | 1 | 2023 | 617 | 0.040 |
Why?
|
| North America | 1 | 2019 | 265 | 0.040 |
Why?
|
| Sickness Impact Profile | 1 | 2018 | 38 | 0.040 |
Why?
|
| Wisconsin | 1 | 2017 | 16 | 0.030 |
Why?
|
| Canada | 1 | 2019 | 337 | 0.030 |
Why?
|
| Hemoglobins | 1 | 2019 | 321 | 0.030 |
Why?
|
| Motor Activity | 1 | 2021 | 521 | 0.030 |
Why?
|
| Survivors | 2 | 2010 | 358 | 0.030 |
Why?
|
| Queensland | 1 | 2017 | 5 | 0.030 |
Why?
|
| Secondary Prevention | 1 | 2019 | 219 | 0.030 |
Why?
|
| Uridine Monophosphate | 1 | 2017 | 8 | 0.030 |
Why?
|
| Fluorenes | 1 | 2017 | 8 | 0.030 |
Why?
|
| Sofosbuvir | 1 | 2017 | 21 | 0.030 |
Why?
|
| Patient Dropouts | 1 | 2017 | 52 | 0.030 |
Why?
|
| Models, Economic | 1 | 2017 | 55 | 0.030 |
Why?
|
| Isometric Contraction | 1 | 2016 | 24 | 0.030 |
Why?
|
| Remission Induction | 1 | 2017 | 306 | 0.030 |
Why?
|
| Ribavirin | 1 | 2017 | 89 | 0.030 |
Why?
|
| Stroke Volume | 1 | 2019 | 535 | 0.030 |
Why?
|
| Heart | 1 | 2021 | 698 | 0.030 |
Why?
|
| Mobile Applications | 1 | 2018 | 108 | 0.030 |
Why?
|
| Ethiodized Oil | 1 | 2016 | 4 | 0.030 |
Why?
|
| Benzimidazoles | 1 | 2017 | 132 | 0.030 |
Why?
|
| Principal Component Analysis | 1 | 2016 | 156 | 0.030 |
Why?
|
| Frail Elderly | 1 | 2016 | 107 | 0.030 |
Why?
|
| Ultrasonography | 2 | 2012 | 989 | 0.030 |
Why?
|
| Ventricular Function, Left | 1 | 2019 | 547 | 0.030 |
Why?
|
| Drug Administration Schedule | 1 | 2017 | 749 | 0.030 |
Why?
|
| Specialization | 1 | 2016 | 80 | 0.030 |
Why?
|
| Exercise | 1 | 2021 | 859 | 0.030 |
Why?
|
| Postoperative Care | 1 | 2017 | 311 | 0.030 |
Why?
|
| Walking | 1 | 2016 | 232 | 0.030 |
Why?
|
| Electronic Health Records | 1 | 2021 | 802 | 0.030 |
Why?
|
| Capecitabine | 1 | 2013 | 18 | 0.030 |
Why?
|
| Disease-Free Survival | 1 | 2016 | 955 | 0.030 |
Why?
|
| Socioeconomic Factors | 1 | 2017 | 899 | 0.030 |
Why?
|
| Necrosis | 1 | 2013 | 210 | 0.030 |
Why?
|
| Cholangitis, Sclerosing | 1 | 2013 | 73 | 0.020 |
Why?
|
| Chemoradiotherapy | 1 | 2013 | 125 | 0.020 |
Why?
|
| Florida | 1 | 2011 | 80 | 0.020 |
Why?
|
| Disease Models, Animal | 1 | 2022 | 4688 | 0.020 |
Why?
|
| Computer Simulation | 1 | 2014 | 698 | 0.020 |
Why?
|
| Neoadjuvant Therapy | 1 | 2013 | 400 | 0.020 |
Why?
|
| Monitoring, Physiologic | 1 | 2013 | 380 | 0.020 |
Why?
|
| Transplantation, Heterotopic | 1 | 2011 | 27 | 0.020 |
Why?
|
| Kidney Failure, Chronic | 1 | 2018 | 898 | 0.020 |
Why?
|
| Perception | 1 | 2011 | 236 | 0.020 |
Why?
|
| Clinical Trials as Topic | 1 | 2014 | 1159 | 0.020 |
Why?
|
| Phenylurea Compounds | 1 | 2010 | 56 | 0.020 |
Why?
|
| Feasibility Studies | 1 | 2011 | 825 | 0.020 |
Why?
|
| Patient Compliance | 1 | 2011 | 473 | 0.020 |
Why?
|
| Mice | 1 | 2022 | 18534 | 0.010 |
Why?
|
| Veterans | 1 | 2016 | 1762 | 0.010 |
Why?
|
| Animals | 1 | 2022 | 34908 | 0.010 |
Why?
|